JANX
NASDAQ
$16.05
Janux Therapeutics Inc (JANX)
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $37.19 (+131.71%)
Market Cap
$976M
Free Cash Flow Yield
-8.05%
Beta (5Y)
1.20
Price Chart
Valuation
Market Cap$976M
P/S71.18
P/B1.02
Profitability
Total Revenue (TTM)$14M
Gross Profit (TTM)-$114M
EBITDA-$155M
Operating Margin-916%
EPS-$1.90
Financial Health
Free Cash Flow Yield-8.05%
Growth & Risk
Beta (5Y)1.20
Sharpe Ratio-0.31